Yen-Yin Lin

CEO
JelloX biotech Inc.

​

Dr. Yen-Yin Lin founded JelloX Biotech Inc. in 2019 and has since served as its CEO, spearheading breakthrough 3-D tissue-clearing chemistry and next-generation digital-pathology R&D while guiding the company’s versatile 3-D + AI clinical platform from concept to product. Dr. Lin has more than 20 years of R&D experience in laser physics and advanced biological imaging, with some 70 peer-reviewed publications and multiple invention patents. A scientist-engineer at heart, he combines deep science with application-driven engineering and leverages a worldwide network spanning leading hospitals, biotech and pharmaceutical firms, and high-tech companies.
 
Under his leadership JelloX has secured FDA listing for its tissue-clearing solution, FDA 510(k) premarket notification approval and TFDA class II SaMD for its MetaLite^® DX , built a robust IP portfolio, and garnered prestigious honors—including the Academic Entrepreneur Pioneer Award, the Future Technology Award, the Business Startup Award, the Boehringer Ingelheim Grass Roots Award, and the Best Bio Startup CEO Award. His strategic vision targets critical gaps in precision oncology—patient–drug matching, tumor-risk assessment, and early detection—through the company’s proprietary MetaLite^® software and 3-D pathology platform. JelloX is now poised to launch the world’s first clinical 3-D pathology diagnostic product in Taiwan during the second half of 2025, ushering in a new era of digital pathology.​

Speech title & Synopsis

Company Profile

JelloX Biotech Inc. is reshaping modern pathology by uniting three-dimensional (3D) digital imaging, artificial intelligence, and on-premise edge computing. Instead of relying on traditional 2-D slides, its proprietary workflow renders entire tissue blocks transparent, captures cellular-level volumetric data, and then reconstructs the specimen in 3D. This added spatial perspective lets pathologists visualize how tumor cells interact with surrounding structures, leading to faster and more accurate diagnoses.
 
Central to the platform are 3D AI algorithms trained to recognize spatial patterns in the most common solid tumors—lung, prostate, breast, head-and-neck, colorectal, and others. These engines quantify intricate features such as tumor-infiltrating lymphocytes, gland morphology, and biomarker co-localization, producing digital “tumor atlases” that guide risk stratification and therapy selection. Compatible with both fresh and formalin-fixed paraffin-embedded (FFPE) samples, the pipeline integrates effortlessly into existing histology labs and augments routine H&E, IHC, and genomic assays.
 
The company’s Panoramic Pathology Platform supports an extensive biomarker panel—HER2, PD-L1, Ki-67, ER, PR, pan-CK, TTF-1, EGFR, CD3, CD4, CD8, CD20, CD31, CD45, among others—delivering multiplexed, spatially resolved metrics in a single read-out. All processing runs on the MetaLite® edge-AI engine, which reduces cloud latency, safeguards patient privacy, and provides real-time reporting within the hospital’s firewall.
 
JelloX works in close partnership with top hospitals, biotech and pharma companies, and leading technology firms to scale its solution across smart hospitals and centralized laboratories. The company is actively seeking new collaborators—from clinical centers to biopharma and tech providers—to accelerate the global adoption of 3D digital pathology and deliver faster, more precise cancer diagnostics.